20170406 Telix Logo.png
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
August 16, 2021 19:55 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LONDON , Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the London-based Great Ormond Street Hospital...
Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL
September 03, 2019 02:00 ET | Autolus Therapeutics plc
Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete...
Autolus Therapeutics to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8
August 02, 2019 09:06 ET | Autolus Therapeutics plc
LONDON, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Participate in Upcoming Investor Conferences in June
May 28, 2019 16:55 ET | Autolus Therapeutics plc
LONDON, May 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
May 14, 2019 06:30 ET | Autolus Therapeutics plc
LONDON, May 14, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on May 14
May 07, 2019 16:05 ET | Autolus Therapeutics plc
LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Proposed Public Offering in the United States
April 08, 2019 16:40 ET | Autolus Therapeutics plc
LONDON, April 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
NotableLabs-Logo-07 (2).png
Oncology Startup Notable Labs Donates its First Pediatric Therapy to Repurposing Non-Profit
January 22, 2019 10:00 ET | Notable Labs
FOSTER CITY, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Notable Labs, a startup that accelerates drug development by matching drugs with patients who are most likely to respond, announced today that...